MERCADO DE TRABAJO
3. TIPOS DE SEGUROS AGRARIOS
17-AAD 17-allylaminogeldanamycin
AMPK adenosine monophosphate-activated protein kinase ARNT aryl hydrocarbon receptor nuclear translocator ATP adenosine triphosphate
CA-IX carbonic anhydrase 9 Cas CRISPR-associated genes ChIP chromatin immunoprecipitation
CRISPR clustered regularly interspaced short palindromic repeats DFX desferrioxamine
FIH-1 factor inhibiting HIF-1
GAPDH glyceraldehyde 3-phosphate dehydrogenase GLUT1 glucose transporter 1
HAT histone acetyltransferase HDAC histone deacetylase
HDACI histone deacetylase inhibitor HIF hypoxia-inducible factor HK2 hexokinase 2
Hsp70 70 kilodalton heat shock proteins Hsp90 90 kilodalton heat shock proteins LDH lactate dehydrogenase
LMB leptomycin B
MG132 carbobenzoxy-Leu-Leu-leucinal ODD oxygen-dependent degradation domain PAS PER-ARNT-SIM
PER period circadian protein PFK2 phosphofructokinase 2 SIM single-minded protein TAD transactivation domain TSA trichostatin A
VEGF vascular endothelial growth factor VHL von Hippel-Lindau tumor suppressor bFGF basic fibroblast growth factor
bHLH basic helix-loop-helix
qRT-PCR quantitative real-time polymerase chain reaction
List of References
Adams, J., Z. P. Chen, B. J. Van Denderen, C. J. Morton, M. W. Parker, L. A. Witters, D. Stapleton and B. E. Kemp (2004). "Intrasteric control of AMPK via the gamma1 subunit AMP allosteric regulatory site." Protein Sci 13(1): 155-165.
Agis-Balboa, R. C., Z. Pavelka, C. Kerimoglu and A. Fischer (2013). "Loss of HDAC5 impairs memory function: implications for Alzheimer's disease." J Alzheimers Dis 33(1): 35-44.
Ahringer, J. (2000). "NuRD and SIN3 histone deacetylase complexes in development." Trends Genet 16(8): 351-356.
An, W. G., M. Kanekal, M. C. Simon, E. Maltepe, M. V. Blagosklonny and L. M. Neckers (1998). "Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha." Nature 392(6674): 405-408.
Arnesen, T., X. Kong, R. Evjenth, D. Gromyko, J. E. Varhaug, Z. Lin, N. Sang, J. Caro and J. R. Lillehaug (2005). "Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha." FEBS Lett 579(28): 6428-6432.
Backs, J., T. Backs, S. Bezprozvannaya, T. A. McKinsey and E. N. Olson (2008). "Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II
responsiveness by oligomerization with histone deacetylase 4." Mol Cell Biol 28(10): 3437-3445.
Bali, P., M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S.
Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto and K. Bhalla (2005). "Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors." J Biol Chem 280(29): 26729-26734.
Bazzaro, M., M. K. Lee, A. Zoso, W. L. Stirling, A. Santillan, M. Shih Ie and R. B. Roden (2006). "Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis." Cancer Res 66(7): 3754-3763.
Bel Aiba, R. S. and A. Gorlach (2003). "Regulation of the hypoxia-inducible transcription factor HIF-1 by reactive oxygen species in smooth muscle cells." Adv Exp Med Biol 536: 171-178.
Bilton, R., N. Mazure, E. Trottier, M. Hattab, M. A. Dery, D. E. Richard, J. Pouyssegur and M. C. Brahimi-Horn (2005). "Arrest-defective-1 protein, an
acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF." Journal of Biological Chemistry 280(35): 31132- 31140.
Black, J. C., A. Mosley, T. Kitada, M. Washburn and M. Carey (2008). "The SIRT2 deacetylase regulates autoacetylation of p300." Mol Cell 32(3): 449-455.
Blagosklonny, M. V., W. G. An, L. Y. Romanova, J. Trepel, T. Fojo and L. Neckers (1998). "p53 inhibits hypoxia-inducible factor-stimulated transcription." J Biol Chem 273(20): 11995-11998.
Blander, G. and L. Guarente (2004). "The Sir2 family of protein deacetylases." Annual Review of Biochemistry 73: 417-435.
Bos, R., P. J. van Diest, J. S. de Jong, P. van der Groep, P. van der Valk and E. van der Wall (2005). "Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer."
Histopathology 46(1): 31-36.
Bosch-Marce, M., H. Okuyama, J. B. Wesley, K. Sarkar, H. Kimura, Y. V. Liu, H. Zhang, M. Strazza, S. Rey, L. Savino, Y. F. Zhou, K. R. McDonald, Y. Na, S. Vandiver, A. Rabi, Y. Shaked, R. Kerbel, T. Lavallee and G. L. Semenza (2007). "Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell
mobilization and recovery of perfusion after limb ischemia." Circ Res 101(12): 1310- 1318.
Bottomley, M. J., P. Lo Surdo, P. Di Giovine, A. Cirillo, R. Scarpelli, F. Ferrigno, P. Jones, P. Neddermann, R. De Francesco, C. Steinkuhler, P. Gallinari and A. Carfi (2008). "Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain." J Biol Chem 283(39): 26694- 26704.
Bouzin, C. and O. Feron (2007). "Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery." Drug Resist Updat 10(3): 109-120.
Brown, J. M. and W. R. Wilson (2004). "Exploiting tumour hypoxia in cancer treatment." Nat Rev Cancer 4(6): 437-447.
Buchner, J. (1999). "Hsp90 & Co. - a holding for folding." Trends Biochem Sci 24(4): 136-141.
Cai, Z., H. Zhong, M. Bosch-Marce, K. Fox-Talbot, L. Wang, C. Wei, M. A. Trush and G. L. Semenza (2008). "Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha." Cardiovasc Res 77(3): 463-470.
Calvani, M., A. Rapisarda, B. Uranchimeg, R. H. Shoemaker and G. Melillo (2006). "Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives
angiogenesis in human endothelial cells." Blood 107(7): 2705-2712.
Carroll, V. A. and M. Ashcroft (2006). "Role of hypoxia-inducible factor (HIF)-
1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway." Cancer Res 66(12): 6264-6270.
Chang, S. R., T. A. McKinsey, C. L. Zhang, J. A. Richardson, J. A. Hill and E. N. Olson (2004). "Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development." Molecular and Cellular Biology 24(19): 8467-8476.
Chen, B. and C. L. Cepko (2009). "HDAC4 regulates neuronal survival in normal and diseased retinas." Science 323(5911): 256-259.
Chen, S. and N. Sang (2011). "Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors." J Biomed Biotechnol 2011: 197946.
Cho, Y. and V. Cavalli (2012). "HDAC5 is a novel injury-regulated tubulin deacetylase controlling axon regeneration." EMBO J 31(14): 3063-3078.
Choudhary, C., C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V. Olsen and M. Mann (2009). "Lysine acetylation targets protein complexes and co- regulates major cellular functions." Science 325(5942): 834-840.
Cong, L., F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini and F. Zhang (2013). "Multiplex genome engineering using CRISPR/Cas systems." Science 339(6121): 819-823.
Daponte, A., M. Ioannou, I. Mylonis, G. Simos, M. Minas, I. E. Messinis and G. Koukoulis (2008). "Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF- 1 alpha) expression in serous ovarian cancer: an immunohistochemical study." BMC Cancer 8: 335.
Demidenko, Z. N., A. Rapisarda, M. Garayoa, P. Giannakakou, G. Melillo and M. V. Blagosklonny (2005). "Accumulation of hypoxia-inducible factor-1alpha is limited by transcription-dependent depletion." Oncogene 24(30): 4829-4838.
Dragu, A., S. Schnurer, C. Surmann-Schmitt, F. Unglaub, U. Kneser and R. E. Horch (2011). "Expression of HIF-1alpha in Ischemia and Reperfusion in Human
Microsurgical Free Muscle Tissue Transfer." Plast Reconstr Surg 127(6): 2293-2300. Drummond, D. C., C. O. Noble, D. B. Kirpotin, Z. Guo, G. K. Scott and C. C. Benz (2005). "Clinical development of histone deacetylase inhibitors as anticancer agents." Annu Rev Pharmacol Toxicol 45: 495-528.
Egger, M., W. Schgoer, A. G. Beer, J. Jeschke, J. Leierer, M. Theurl, S. Frauscher, O. M. Tepper, A. Niederwanger, A. Ritsch, M. Kearney, J. Wanschitz, G. C. Gurtner, R. Fischer-Colbrie, G. Weiss, H. Piza-Katzer, D. W. Losordo, J. R. Patsch, P.
Schratzberger and R. Kirchmair (2007). "Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1alpha- and basic FGF-dependent pathway in muscle cells." FASEB J 21(11): 2906-2917.
Epstein, A. C. R., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield and P. J. Ratcliffe (2001). "C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation." Cell 107(1): 43-54.
Escuin, D., E. R. Kline and P. Giannakakou (2005). "Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function." Cancer Res 65(19): 9021-9028.
Fath, D. M., X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro and N. Sang (2006). "Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha." J Biol Chem 281(19): 13612-13619.
Fischle, W., F. Dequiedt, M. J. Hendzel, M. G. Guenther, M. A. Lazar, W. Voelter and E. Verdin (2002). "Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR." Mol Cell 9(1): 45-57.
Fischle, W., S. Emiliani, M. J. Hendzel, T. Nagase, N. Nomura, W. Voelter and E. Verdin (1999). "A new family of human histone deacetylases related to
Saccharomyces cerevisiae HDA1p." J Biol Chem 274(17): 11713-11720.
Fisher, T. S., S. Des Etages, L. Hayes, K. Crimin and B. Y. Li (2005). "Analysis of ARD1 function in hypoxia response using retroviral RNA interference." Journal of Biological Chemistry 280(18): 17749-17757.
Gao, L., M. A. Cueto, F. Asselbergs and P. Atadja (2002). "Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family." J Biol Chem 277(28): 25748-25755.
Gao, W., G. Ferguson, P. Connell, T. Walshe, R. Murphy, Y. A. Birney, C. O'Brien and P. A. Cahill (2007). "High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1alpha-dependent pathway." J Mol Cell Cardiol 42(3): 609-619.
Geng, H., C. T. Harvey, J. Pittsenbarger, Q. Liu, T. M. Beer, C. Xue and D. Z. Qian (2011). "HDAC4 protein regulates HIF1alpha protein lysine acetylation and cancer cell response to hypoxia." J Biol Chem 286(44): 38095-38102.
Giaccia, A., B. G. Siim and R. S. Johnson (2003). "HIF-1 as a target for drug development." Nat Rev Drug Discov 2(10): 803-811.
Giordano, F. J. (2005). "Oxygen, oxidative stress, hypoxia, and heart failure." J Clin Invest 115(3): 500-508.
Gisvold, S. E. and P. Safar (1982). "Systematic studies of cerebral resuscitation potentials after global brain ischemia." Crit Care Med 10(7): 466-470.
Go, A. S., D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, S. Dai, E. S. Ford, C. S. Fox, S. Franco, H. J. Fullerton, C. Gillespie, S. M. Hailpern, J. A. Heit, V. J. Howard, M. D. Huffman, S. E. Judd, B. M. Kissela, S. J. Kittner, D. T. Lackland, J. H. Lichtman, L. D. Lisabeth, R. H. Mackey, D. J. Magid, G. M. Marcus, A. Marelli, D. B. Matchar, D. K. McGuire, E. R. Mohler, 3rd, C. S. Moy, M. E. Mussolino, R. W. Neumar, G. Nichol, D. K. Pandey, N. P. Paynter, M. J. Reeves, P. D. Sorlie, J. Stein, A. Towfighi, T. N. Turan, S. S. Virani, N. D. Wong, D. Woo, M. B. Turner, C. American Heart Association Statistics and S. Stroke Statistics (2014). "Heart disease and stroke statistics--2014 update: a report from the American Heart Association." Circulation 129(3): e28-e292.
Goetz, M. P., D. O. Toft, M. M. Ames and C. Erlichman (2003). "The Hsp90
chaperone complex as a novel target for cancer therapy." Annals of Oncology 14(8): 1169-1176.
Gomez-Raposo, C., M. Mendiola, J. Barriuso, E. Casado, D. Hardisson and A. Redondo (2009). "Angiogenesis and ovarian cancer." Clin Transl Oncol 11(9): 564- 571.
Goodson, M., B. A. Jonas and M. A. Privalsky (2005). "Corepressors: custom tailoring and alterations while you wait." Nucl Recept Signal 3: e003.
Granger, A., I. Abdullah, F. Huebner, A. Stout, T. Wang, T. Huebner, J. A. Epstein and P. J. Gruber (2008). "Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice." FASEB J 22(10): 3549-3560.
Greco, T. M., F. Yu, A. J. Guise and I. M. Cristea (2011). "Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation." Mol Cell Proteomics 10(2): M110 004317.
Haggarty, S. J., K. M. Koeller, J. C. Wong, C. M. Grozinger and S. L. Schreiber (2003). "Domain-selective small-molecule inhibitor of histone deacetylase 6
(HDAC6)-mediated tubulin deacetylation." Proc Natl Acad Sci U S A 100(8): 4389- 4394.
Hasselgren, P. O. (2007). "Ubiquitination, phosphorylation, and acetylation--triple threat in muscle wasting." J Cell Physiol 213(3): 679-689.
Hirota, K. and G. L. Semenza (2006). "Regulation of angiogenesis by hypoxia- inducible factor 1." Crit Rev Oncol Hematol 59(1): 15-26.
Hu, C. J., A. Sataur, L. Wang, H. Chen and M. C. Simon (2007). "The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1alpha and HIF-2alpha." Mol Biol Cell 18(11): 4528-4542.
Hu, C. J., L. Y. Wang, L. A. Chodosh, B. Keith and M. C. Simon (2003).
"Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation." Mol Cell Biol 23(24): 9361-9374.
Huang, E. Y., J. Zhang, E. A. Miska, M. G. Guenther, T. Kouzarides and M. A. Lazar (2000). "Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway." Genes Dev 14(1): 45-54.
Huang, L. E., J. Gu, M. Schau and H. F. Bunn (1998). "Regulation of hypoxia- inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway." Proc Natl Acad Sci U S A 95(14): 7987-7992. Huang, Y., R. P. Hickey, J. L. Yeh, D. Liu, A. Dadak, L. H. Young, R. S. Johnson and F. J. Giordano (2004). "Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart." FASEB J 18(10): 1138-1140.
Hubbert, C., A. Guardiola, R. Shao, Y. Kawaguchi, A. Ito, A. Nixon, M. Yoshida, X. F. Wang and T. P. Yao (2002). "HDAC6 is a microtubule-associated deacetylase." Nature 417(6887): 455-458.
Ikenoue, T., K. Inoki, B. Zhao and K. L. Guan (2008). "PTEN acetylation modulates its interaction with PDZ domain." Cancer Res 68(17): 6908-6912.
Inoue, T., M. Hiratsuka, M. Osaki and M. Oshimura (2007). "The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation." Cell Cycle 6(9): 1011- 1018.
Isaacs, J. S., Y. J. Jung, D. R. Mole, S. Lee, C. Torres-Cabala, Y. L. Chung, M. Merino, J. Trepel, B. Zbar, J. Toro, P. J. Ratcliffe, W. M. Linehan and L. Neckers (2005). "HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability." Cancer Cell 8(2): 143-153.
Ishii, Y., S. Waxman and D. Germain (2007). "Targeting the ubiquitin-proteasome pathway in cancer therapy." Anticancer Agents Med Chem 7(3): 359-365.
Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane and W. G. Kaelin, Jr. (2001). "HIFalpha targeted for VHL-mediated
destruction by proline hydroxylation: implications for O2 sensing." Science 292(5516): 464-468.
Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh and P. J. Ratcliffe (2001). "Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation." Science 292(5516): 468-472.
Jeong, J. W., M. K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, M. A. Yoo, E. J. Song, K. J. Lee and K. W. Kim (2002). "Regulation and destabilization of HIF- 1alpha by ARD1-mediated acetylation." Cell 111(5): 709-720.
Jiang, H. and Y. Feng (2006). "Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer." Int J Gynecol Cancer 16 Suppl 1: 405-412.
Jibb, L. A. and J. G. Richards (2008). "AMP-activated protein kinase activity during metabolic rate depression in the hypoxic goldfish, Carassius auratus." J Exp Biol 211(Pt 19): 3111-3122.
Joazeiro, C. A., K. C. Anderson and T. Hunter (2006). "Proteasome inhibitor drugs on the rise." Cancer Res 66(16): 7840-7842.
Johnstone, R. W. and J. D. Licht (2003). "Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?" Cancer Cell 4(1): 13-18.
Joseph, J., G. Mudduluru, S. Antony, S. Vashistha, P. Ajitkumar and K.
Somasundaram (2004). "Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer
metastasis by NaB." Oncogene 23(37): 6304-6315.
Kaelin, W. G., Jr. (2005). "The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing." Biochem Biophys Res Commun 338(1): 627-638.
Kaelin, W. G., Jr. (2007). "The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma." Clin Cancer Res 13(2 Pt 2): 680s-684s.
Kallio, P. J., K. Okamoto, S. O'Brien, P. Carrero, Y. Makino, H. Tanaka and L. Poellinger (1998). "Signal transduction in hypoxic cells: inducible nuclear
translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1alpha." EMBO J 17(22): 6573-6586.
Kasper, L. H., F. Boussouar, K. Boyd, W. Xu, M. Biesen, J. Rehg, T. A. Baudino, J. L. Cleveland and P. K. Brindle (2005). "Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression." EMBO J 24(22): 3846-3858. Kato, H., S. Tamamizu-Kato and F. Shibasaki (2004). "Histone deacetylase 7 associates with hypoxia-inducible factor 1alpha and increases transcriptional activity." J Biol Chem 279(40): 41966-41974.
Kim, M. S., H. J. Kwon, Y. M. Lee, J. H. Baek, J. E. Jang, S. W. Lee, E. J. Moon, H. S. Kim, S. K. Lee, H. Y. Chung, C. W. Kim and K. W. Kim (2001). "Histone
deacetylases induce angiogenesis by negative regulation of tumor suppressor genes." Nat Med 7(4): 437-443.
Kim, S. H., K. W. Kim and J. W. Jeong (2007). "Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia- inducible factor-1alpha suppression." Oncol Rep 17(4): 793-797.
Kong, D., E. J. Park, A. G. Stephen, M. Calvani, J. H. Cardellina, A. Monks, R. J. Fisher, R. H. Shoemaker and G. Melillo (2005). "Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity." Cancer Res 65(19): 9047-9055.
Kong, X., Z. Lin, D. Liang, D. Fath, N. Sang and J. Caro (2006). "Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal
degradation of hypoxia-inducible factor 1alpha." Mol Cell Biol 26(6): 2019-2028. Kovacs, J. J., P. J. Murphy, S. Gaillard, X. Zhao, J. T. Wu, C. V. Nicchitta, M. Yoshida, D. O. Toft, W. B. Pratt and T. P. Yao (2005). "HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor." Mol Cell 18(5): 601-607.
Krishnan, J., M. Suter, R. Windak, T. Krebs, A. Felley, C. Montessuit, M. Tokarska- Schlattner, E. Aasum, A. Bogdanova, E. Perriard, J. C. Perriard, T. Larsen, T. Pedrazzini and W. Krek (2009). "Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy." Cell Metab 9(6): 512-524.
Laderoute, K. R., K. Amin, J. M. Calaoagan, M. Knapp, T. Le, J. Orduna, M. Foretz and B. Viollet (2006). "5'-AMP-activated protein kinase (AMPK) is induced by low- oxygen and glucose deprivation conditions found in solid-tumor microenvironments." Molecular and Cellular Biology 26(14): 5336-5347.
Lage, R., C. Dieguez, A. Vidal-Puig and M. Lopez (2008). "AMPK: a metabolic gauge regulating whole-body energy homeostasis." Trends Mol Med 14(12): 539-549. Lahm, A., C. Paolini, M. Pallaoro, M. C. Nardi, P. Jones, P. Neddermann, S.
Sambucini, M. J. Bottomley, P. Lo Surdo, A. Carfi, U. Koch, R. De Francesco, C. Steinkuhler and P. Gallinari (2007). "Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases." Proc Natl Acad Sci U S A 104(44): 17335- 17340.
Lando, D., J. J. Gorman, M. L. Whitelaw and D. J. Peet (2003). "Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation." Eur J Biochem 270(5): 781-790.
Lando, D., D. J. Peet, D. A. Whelan, J. J. Gorman and M. L. Whitelaw (2002). "Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch." Science 295(5556): 858-861.
Lao, T., S. Chen and N. Sang (2012). "Two mutations impair the stability and function of ubiquitin-activating enzyme (E1)." J Cell Physiol 227(4): 1561-1568. Lee, M., J. T. Hwang, H. J. Lee, S. N. Jung, I. Kang, S. G. Chi, S. S. Kim and J. Ha (2003). "AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells." J Biol Chem 278(41): 39653-39661.
Lemercier, C., A. Verdel, B. Galloo, S. Curtet, M. P. Brocard and S. Khochbin (2000). "mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A
Levenson, J. M., K. J. O'Riordan, K. D. Brown, M. A. Trinh, D. L. Molfese and J. D. Sweatt (2004). "Regulation of histone acetylation during memory formation in the hippocampus." J Biol Chem 279(39): 40545-40559.
Levy, D., R. J. Garrison, D. D. Savage, W. B. Kannel and W. P. Castelli (1990). "Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study." N Engl J Med 322(22): 1561-1566.
Li, Y., Z. Yuan, B. Liu, E. A. Sailhamer, C. Shults, G. C. Velmahos, M. Demoya and H. B. Alam (2008). "Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition." J Trauma 64(4): 863-870; discussion 870-861. Liao, D. and R. S. Johnson (2007). "Hypoxia: a key regulator of angiogenesis in cancer." Cancer Metastasis Rev 26(2): 281-290.
Licht, A. H., F. Muller-Holtkamp, I. Flamme and G. Breier (2006). "Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic
cardiovascular development." Blood 107(2): 584-590.
Lisman, J., H. Schulman and H. Cline (2002). "The molecular basis of CaMKII function in synaptic and behavioural memory." Nat Rev Neurosci 3(3): 175-190. Livak, K. J. and T. D. Schmittgen (2001). "Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method." Methods 25(4): 402-408.
Loenarz, C., M. L. Coleman, A. Boleininger, B. Schierwater, P. W. Holland, P. J. Ratcliffe and C. J. Schofield (2011). "The hypoxia-inducible transcription factor pathway regulates oxygen sensing in the simplest animal, Trichoplax adhaerens." EMBO Rep 12(1): 63-70.
Lofstedt, T., E. Fredlund, L. Holmquist-Mengelbier, A. Pietras, M. Ovenberger, L. Poellinger and S. Pahlman (2007). "Hypoxia inducible factor-2alpha in cancer." Cell Cycle 6(8): 919-926.
Luo, W., J. Zhong, R. Chang, H. Hu, A. Pandey and G. L. Semenza (2010). "Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1alpha but Not HIF-2alpha." J Biol Chem 285(6): 3651-3663.
Mabjeesh, N. J., D. Escuin, T. M. LaVallee, V. S. Pribluda, G. M. Swartz, M. S. Johnson, M. T. Willard, H. Zhong, J. W. Simons and P. Giannakakou (2003). "2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF." Cancer Cell 3(4): 363-375.
Maltepe, E., G. W. Krampitz, K. M. Okazaki, K. Red-Horse, W. Mak, M. C. Simon and S. J. Fisher (2005). "Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta." Development 132(15): 3393-3403. Manabe, H., Y. Nasu, T. Komiyama, T. Furumatsu, A. Kitamura, S. Miyazawa, Y. Ninomiya, T. Ozaki, H. Asahara and K. Nishida (2008). "Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts." Inflamm Res 57(1): 4-10.
Manalo, D. J., A. Rowan, T. Lavoie, L. Natarajan, B. D. Kelly, S. Q. Ye, J. G. Garcia and G. L. Semenza (2005). "Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1." Blood 105(2): 659-669.
Marek, L., A. Hamacher, F. K. Hansen, K. Kuna, H. Gohlke, M. U. Kassack and T. Kurz (2013). "Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells." J Med Chem 56(2): 427-436.
Marks, P. A. and M. Dokmanovic (2005). "Histone deacetylase inhibitors: discovery and development as anticancer agents." Expert Opinion on Investigational Drugs 14(12): 1497-1511.
Marks, P. A., V. M. Richon, R. Breslow and R. A. Rifkind (2001). "Histone deacetylase inhibitors as new cancer drugs." Curr Opin Oncol 13(6): 477-483. Matsuyama, A., T. Shimazu, Y. Sumida, A. Saito, Y. Yoshimatsu, D. Seigneurin- Berny, H. Osada, Y. Komatsu, N. Nishino, S. Khochbin, S. Horinouchi and M. Yoshida (2002). "In vivo destabilization of dynamic microtubules by HDAC6- mediated deacetylation." EMBO J 21(24): 6820-6831.
Maynard, M. A., A. J. Evans, T. Hosomi, S. Hara, M. A. Jewett and M. Ohh (2005). "Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down- regulated in renal cell carcinoma." FASEB J 19(11): 1396-1406.
McGee, S. L. and M. Hargreaves (2010). "Histone modifications and skeletal muscle metabolic gene expression." Clin Exp Pharmacol Physiol 37(3): 392-396.
McGee, S. L., D. Sparling, A. L. Olson and M. Hargreaves (2006). "Exercise
increases MEF2- and GEF DNA-binding activity in human skeletal muscle." FASEB J 20(2): 348-349.
McGee, S. L., B. J. van Denderen, K. F. Howlett, J. Mollica, J. D. Schertzer, B. E. Kemp and M. Hargreaves (2008). "AMP-activated protein kinase regulates GLUT4 transcription by phosphorylating histone deacetylase 5." Diabetes 57(4): 860-867. McKinsey, T. A., C. L. Zhang and E. N. Olson (2000). "Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5." Proc Natl Acad Sci U S A 97(26): 14400-14405.
McKinsey, T. A., C. L. Zhang and E. N. Olson (2001). "Identification of a signal- responsive nuclear export sequence in class II histone deacetylases." Mol Cell Biol 21(18): 6312-6321.
Mie Lee, Y., S. H. Kim, H. S. Kim, M. Jin Son, H. Nakajima, H. Jeong Kwon and K. W. Kim (2003). "Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity." Biochem Biophys Res Commun 300(1): 241-246.
Milde, T., I. Oehme, A. Korshunov, A. Kopp-Schneider, M. Remke, P. Northcott, H. E. Deubzer, M. Lodrini, M. D. Taylor, A. von Deimling, S. Pfister and O. Witt (2010). "HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth." Clin Cancer Res 16(12): 3240-3252.
Miska, E. A., C. Karlsson, E. Langley, S. J. Nielsen, J. Pines and T. Kouzarides (1999). "HDAC4 deacetylase associates with and represses the MEF2 transcription factor." EMBO J 18(18): 5099-5107.
Miska, E. A., E. Langley, D. Wolf, C. Karlsson, J. Pines and T. Kouzarides (2001). "Differential localization of HDAC4 orchestrates muscle differentiation." Nucleic Acids Res 29(16): 3439-3447.
Miyata, Y. (2005). "Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents." Curr Pharm Des 11(9): 1131-1138.
Mungai, P. T., G. B. Waypa, A. Jairaman, M. Prakriya, D. Dokic, M. K. Ball and P. T. Schumacker (2011). "Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels." Molecular and Cellular Biology 31(17): 3531-3545.
Murray-Rust, T. A., N. J. Oldham, K. S. Hewitson and C. J. Schofield (2006).
"Purified recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-1alpha fragments in vitro." FEBS Lett 580(8): 1911-1918.
Murry, C. E., R. B. Jennings and K. A. Reimer (1986). "Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium." Circulation 74(5): 1124-1136.
Neckers, L. and K. Neckers (2005). "Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update." Expert Opin Emerg Drugs 10(1): 137-149.
Newcomb, E. W., Y. Lukyanov, T. Schnee, M. A. Ali, L. Lan and D. Zagzag (2006). "Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug." Int J Oncol 28(5): 1121-1130.
North, B. J., B. L. Marshall, M. T. Borra, J. M. Denu and E. Verdin (2003). "The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase." Mol Cell 11(2): 437-444.
Pajusola, K., J. Kunnapuu, S. Vuorikoski, J. Soronen, H. Andre, T. Pereira, P. Korpisalo, S. Yla-Herttuala, L. Poellinger and K. Alitalo (2005). "Stabilized HIF- 1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer." FASEB J 19(10): 1365-1367.
Patel, T. H., H. Kimura, C. R. Weiss, G. L. Semenza and L. V. Hofmann (2005). "Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an